Cubist Pharma (NASDAQ: CBST) announced Friday after the close that the FDA approved ZERBAXA for the treatment of adults with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE